Civil justice reform. The words don't come trippingly off the tongue. I was trained as a lawyer, and its hard for me to muster much excitement for the topic.
Most Recent Posts
We've done a lot of writing this week about issues pertaining to the biopharmaceutical sector, but we're just one small chunk of health care. A lot of unrelated articles have caught our eyes this week, and we think they're worth sharing with you.
This week, Disruptive Women in Health Care unveiled a new eBook entitled, Innovation Nation: Recognizing the Benefits of Innovation in Health Care. This compilation of blog posts written by several esteemed women in the health care sector is an interesting read. Individually and collectively, their message is clear: Innovation is crucial to the well-being of our health care system.
Perhaps you have seen an especially moving column on Forbes's Web site that is getting a lot of attention - and rightfully so. It's going to run in their paper issue next week, but the way it's spreading around the Web like wildfire, I have a feeling everyone will have seen it by then.
PhRMA, like nearly every workplace in America, employs men and women who have proudly served this nation in its armed forces and who remain active in the reserves.
Last week we talked a bit about how improved adherence can lead to better health and lower overall healthcare costs.
Today, NPR Blog is addressing the issue, reporting that only half of Americans take their prescription medicines as directed. They also share some recommendations from Express Scripts that are worth checking out.
I just addressed the Pharma IQ conference, Winning the War Against Counterfeiters, here in Amsterdam.
On Friday, Health Affairs Blog featured a post by health policy attorney Paul Kim that brought to light the overwhelming lack of attention on the life sciences when discussing innovation in America's policy arena.
We at PhRMA often talk about the drug development process: it typically starts with many thousands of compounds in the discovery phase, whittled down to five that make it to clinical trials, one of which will eventually gain FDA approval - and only two out of those 10 will ever recoup the average investment in R&D required to develop the drug and secure that regulatory approval.
We talk about how long it takes and how expensive the R&D process is - an average of $1.3 billion and 10 to 15 years.
Amidst today's flowers and chocolates and candlelight suppers, take a few moments to remember that the heart is a bit more complicated than pastel candy stamped "Be Mine."
Sure, you need it to love. But you also need it to live.
The American Heart Association has some great information on how to take better care of your heart, from nutrition to stress management to exercise.
Run an internet search of "counterfeit drugs." You'll be stunned by how many stories there are about the growing worldwide threat of counterfeit medicines.
As the first week of blogging from PhRMA wraps up, I thought it would be good to point back to a couple of posts that linked to some great information.
First, there's Meet the Chartpack, introducing a great resource that brings together a ton of useful information about America's biopharmaceutical research sector.
They can rest assured that America's biopharmaceutical research companies are working to create success stories for ALS (also known as Lou Gehrig's Diseases) and many other rare conditions.